Milestone Pharmaceuticals Inc. (MIST) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Milestone Pharmaceuticals is a biopharmaceutical company focused on cardiovascular medicines. The company recently launched its first commercial product, CARDAMYST (etripamil) nasal spray, in U.S. retail pharmacies in February 2026 following FDA approval in December 2025 for the treatment of paroxysmal supraventricular tachycardia (PSVT). The company is also advancing a Phase 3 clinical trial for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR).
Key Financial Metrics
| Metric (in thousands USD) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $559 | $0 | $797 | $0 |
| Net Loss | $(28,614) | $(12,966) | $(54,680) | $(33,727) |
| Net Loss Per Share | $(0.21) | $(0.20) | $(0.41) | $(0.51) |
| Operating Expenses | $26,189 | $12,531 | $50,090 | $33,054 |
| Research & Development | $3,509 | $3,669 | $6,760 | $8,647 |
| Selling, General & Admin | $22,648 | $8,862 | $43,284 | $24,407 |
| Cash & Equivalents (End of Period) | $169,728 (as of June 30, 2026) | |||
| Total Debt & Obligations | $140,970 (Convertible Notes + Royalty Obligation) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first product revenue of $0.6 million in Q2 2026, compared to zero in the prior year, driven by the commercial launch of CARDAMYST.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses increased by 155.6% year-over-year in Q2 (from $8.9M to $22.6M) due to the deployment of a national sales force and commercial infrastructure.
- Interest Expense: Interest expense rose significantly (396.9% increase in Q2) primarily due to the accrual of non-cash interest on a new $75 million royalty financing obligation closed in January 2026.
- Liquidity Position: Cash and cash equivalents increased from $73.0 million at year-end 2025 to $169.7 million at June 30, 2026, bolstered by the $75 million royalty financing proceeds and $17.4 million from warrant exercises.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects operating losses to continue as the company invests in commercialization. The company believes current cash resources ($170.6 million including short-term investments) are sufficient to fund operations for at least the next 12 months.
- Development Pipeline: The Phase 3 trial for AFib-RVR is underway, with the first patient expected to enroll in the second half of 2026. An MAA for the European Union was submitted in November 2025.
- Key Risks:
- Capital Requirements: Continued reliance on equity or debt financing if product revenues do not scale quickly enough to cover commercialization costs.
- Royalty Obligation: The $75 million royalty financing carries a high effective interest rate (approx. 19%) and repayment is tied to future net sales, creating significant interest expense volatility.
- Market Adoption: Success depends on physician adoption of CARDAMYST as a "pill-in-the-pocket" alternative to emergency room visits for PSVT.
Investor Verification Checklist
- Revenue Quality: Verify the gross-to-net revenue adjustments (rebates, chargebacks, returns) as the company is in the early stages of commercialization and estimates may fluctuate.
- Royalty Financing Terms: Review the specific tiered royalty percentages (7% to 1%) and the impact of the 19% effective interest rate on future earnings.
- Commercial Spend Efficiency: Monitor the ratio of SG&A spend to revenue growth to assess the efficiency of the sales force deployment.
- Inventory Valuation: Confirm that inventory costs are being capitalized correctly post-FDA approval and assess any potential write-downs for pre-approval inventory.
- Warrant Exercises: Track the remaining unexercised Series A and B warrants and their potential dilution impact.